Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-44

Great post. it would make sense for them to take the hit from placing the next Her2 trial on hold stating safety is great but more work is needed before that can start. Saves em around $50m? in a challenging environment that no one would give them anyway based on current performance. Then call out a pivot to do exactly as you say - relentless focus on capturing MRI market and a cap raise to fund the preparedness & pursuit of same. Once revenue is trickling in tey will have be able to raise funds to start trialling again.

Bob can sens us a cut of his fees when they implement.... and just for the posters here, I'd buy shares with it as a show of confidence...

GLAH looks like you all need it atm.